Literature DB >> 20456827

Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation.

Aws Alshamsan1, Samar Hamdy, Saswati Das, Afsaneh Lavasanifar, John Samuel, Ayman O S El-Kadi.   

Abstract

PURPOSE: Tumors can escape immune eradication by harnessing dendritic cell (DC) maturation. However, DC types used as in vitro models to study tumor-mediated immunosuppression possess fundamental variability that could influence research outcomes. Therefore, we assessed the behavior of two distinct murine DC models upon exposure to tumor-conditioned medium of B16.F10 melanoma (B16-CM).
METHODS: Using primary bone-marrow derived dendritic cells (BMDCs) or immortalized DC2.4 cell line, we evaluated the level of signal transducer and activator of transcription 3 (STAT3) phosphorylation by Western blot as a molecular parameter. We also examined the surface expression of co-stimulatory molecules on DCs by flow cytometry as a phenotypic parameter.
RESULTS: Our results revealed critical discrepancies between the two models in response to tumor-conditioned medium. While conditioned medium was able to induce STAT3 phosphorylation in BMDCs, it did not significantly induce STAT3 phosphorylation in DC2.4 cell line. Moreover, only in BMDCs, the expression of CD86 and CD40 was remarkably downregulated by B16-CM and was not totally recovered after LPS stimulation. In contrast, DC2.4 cells did not show any signs of harnessed maturation upon exposure to B16-CM.
CONCLUSIONS: In order to study the effect of tumor-mediated immunosuppression on DC maturation in vitro via tumor-induction of STAT3 activation, primary BMDCs are more reliable as a model than DC2.4.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456827     DOI: 10.18433/j37598

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  8 in total

1.  STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Authors:  Aws Alshamsan; Samar Hamdy; Azita Haddadi; John Samuel; Ayman O S El-Kadi; Hasan Uludağ; Afsaneh Lavasanifar
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

Review 2.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

3.  Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.

Authors:  Kristian M Hargadon; Johnathan D Bishop; John P Brandt; Zachary C Hand; Yonathan T Ararso; Osric A Forrest
Journal:  Immunol Cell Biol       Date:  2015-05-26       Impact factor: 5.126

4.  Recombinant human IL-37 inhibited endometriosis development in a mouse model through increasing Th1/Th2 ratio by inducing the maturation of dendritic cells.

Authors:  Lijie Li; Zhouzhou Liao; Mingzhu Ye; Jianfa Jiang
Journal:  Reprod Biol Endocrinol       Date:  2021-08-24       Impact factor: 5.211

5.  Tumor-altered dendritic cell function: implications for anti-tumor immunity.

Authors:  Kristian M Hargadon
Journal:  Front Immunol       Date:  2013-07-11       Impact factor: 7.561

Review 6.  Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma.

Authors:  Jingyu Wang; Fang Shen; Ying Yao; Lin-Lin Wang; Yongjian Zhu; Jue Hu
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

Review 7.  The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells.

Authors:  Leila Asef-Kabiri; Hassan Yousefi; Reza Hosseini; Hamzeh Sarvnaz; Majid Salehi; Mohammad Esmaeil Akbari; Nahid Eskandari
Journal:  Mol Cancer       Date:  2021-06-02       Impact factor: 27.401

8.  Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.

Authors:  Tu-Xiong Huang; Xiang-Yu Tan; Hui-Si Huang; Yu-Ting Li; Bei-Lei Liu; Kai-Sheng Liu; Xinchun Chen; Zhe Chen; Xin-Yuan Guan; Chang Zou; Li Fu
Journal:  Gut       Date:  2021-03-10       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.